Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer PatientsSandra E. Ghayad, Pascale A. Cohen|Recent Patents on Anti-Cancer Drug Discovery|2009Cited by 162
ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and InvasionJulie A. Vendrell, Pascale A. Cohen, Aurélie Thollet et al.|Cancer Research|2012Cited by 131
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathwaysSandra E. Ghayad, Pascale A. Cohen, Julie A. Vendrell et al.|International Journal of Cancer|2009Cited by 131
A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cellsJulie A. Vendrell, Pascale A. Cohen, Sandra E. Ghayad et al.|Oncogene|2007Cited by 92
mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levelsSandra E. Ghayad, Pascale A. Cohen, Ivan Bièche et al.|Cancer Science|2008Cited by 76